Breath test could ‘revolutionise’ pancreatic cancer treatment

Published: 29 October 2025. The English Chronicle Desk. The English Chronicle Online.

A groundbreaking new breath test developed by scientists at Imperial College London could transform the way pancreatic cancer is detected and treated. Researchers and cancer charities are calling it a “revolutionary” advancement that may finally offer a reliable way to diagnose one of the deadliest forms of cancer in its earliest stages — when treatment has the greatest chance of success.

Pancreatic Cancer UK, which is funding the large-scale study, has described the project as “the most significant step toward a life-saving breakthrough in 50 years.” The charity and its research partners hope that the breath test will become a simple diagnostic tool available in GP surgeries within five years, potentially saving thousands of lives.

Pancreatic cancer is often called a “silent killer” because its early symptoms — including indigestion, fatigue, or mild abdominal and back pain — are vague and easily mistaken for other illnesses. By the time the disease is diagnosed, it has often already spread to other organs, making surgery or curative treatment impossible. Recent audits paint a grim picture: 62 per cent of patients in England and 65 per cent in Wales are diagnosed at stage four. Survival rates are among the worst of any major cancer, with around one in five patients dying within a month of diagnosis.

The new breath test offers a potential breakthrough. Instead of relying on expensive and time-consuming scans or hospital referrals, the test analyses a patient’s exhaled breath for “volatile organic compounds” — tiny chemical molecules that circulate in the bloodstream and are expelled through the lungs. Researchers have discovered that specific combinations of these compounds can indicate the presence of pancreatic cancer, even before symptoms become apparent.

The large-scale trial will involve 6,000 patients across 40 sites in the UK who present with unexplained symptoms that could indicate cancer. If successful, the test could be rolled out nationwide, providing results to GPs within three days and enabling earlier interventions that could extend survival and improve quality of life.

The project builds on a smaller, earlier study conducted over two years with 700 participants, which delivered what scientists called “promising” results. The expansion of the trial marks a pivotal moment in pancreatic cancer research. By identifying unique molecular patterns in the breath, the test could give doctors a non-invasive, cost-effective, and rapid diagnostic tool that significantly changes patient outcomes.

Pancreatic Cancer UK chief executive Diana Jupp hailed the development as a potential game-changer. “The breath test has the potential to revolutionise the early detection of pancreatic cancer. It is, undoubtedly, the most significant step toward a lifesaving breakthrough in 50 years,” she said. “Thousands of patients with an unknown diagnosis will now help refine it in the real world. This is the first pancreatic cancer breath test to ever reach a national clinical trial of this scale. That in itself makes this a moment of real, tangible hope.”

Jupp also acknowledged the decades of frustration that have defined pancreatic cancer research, where progress has often been limited by the complexity of the disease and the absence of early detection tools. “For decades, the deadliest common cancer has been seen as too great a challenge to solve, but we are determined to keep pushing the boundaries of what’s thought possible,” she added.

Professor George Hanna, head of the department of surgery and cancer at Imperial College London, echoed her optimism, noting that early findings had already demonstrated remarkable accuracy. “If our findings from the initial phase of the breath test study can be validated in a population of patients with an unknown diagnosis, it has huge potential to influence clinical practice and pancreatic cancer referral pathways,” he explained. “The funding announced today means we can now move quickly to that patient validation stage, which is a very exciting next step for us.”

The scale of the new trial represents a shift in how cancer research is being approached — prioritising accessibility, real-world testing, and integration into primary care. Experts hope that if the test proves effective, it will not only detect pancreatic cancer earlier but could eventually be adapted to screen for other cancers as well.

Pancreatic Cancer UK’s £1.1 million investment underscores the urgency of addressing a disease that has seen little improvement in survival rates over decades. Currently, only about 7 per cent of patients live five years beyond their diagnosis, compared with over 50 per cent for many other common cancers. Early detection, experts argue, is the key to closing this survival gap.

Dr. Fiona Hardie, a clinical oncologist not directly involved in the study, described the breath test as a “genuinely exciting development.” She added: “If we can diagnose pancreatic cancer before it spreads, we can offer surgery and treatment options that are simply not possible in late-stage disease. That could double or even triple survival rates in the long run.”

The breath test also represents an opportunity to reduce pressure on the NHS by streamlining diagnosis. Currently, suspected cancer patients are referred for imaging scans such as CT or MRI, which can take weeks to arrange and interpret. A quick, non-invasive breath test available in GP clinics could shorten this pathway dramatically, ensuring that patients at risk receive immediate attention.

As the trial begins, both researchers and patients are hopeful that this initiative will mark the start of a new era in cancer diagnostics. For those affected by pancreatic cancer, even incremental progress can make a world of difference. But if this test delivers on its promise, it could fundamentally change the trajectory of one of medicine’s most challenging and deadly diseases.